A modular DBCO-azide click-chemistry approach is developed to functionalize LNPs with a high-affinity CD4 nanobody, enabling precise CD4 receptor-directed delivery to human CD4+ T cells, establishing CD4-nanobody LNPs as a versatile platform for targeted mRNA and gene-editing delivery.
Abstract
CD4+ T cells orchestrate adaptive immunity and strategies that enable their genetic reprogramming hold promise for treating cancer, immune dysregulation and infectious diseases such as HIV. However, current T cell engineering approaches rely heavily on ex vivo manipulation, which is labor-intensive, costly, and can alter cell phenotypes. Lipid nanoparticles (LNPs) offer a scalable nonviral alternative, yet conventional formulations show minimal interaction with lymphocytes and are rapidly cleared by the liver. In this study, we develop a modular DBCO-azide click-chemistry approach to functionalize LNPs with a high-affinity CD4 nanobody, enabling precise CD4 receptor-directed delivery to human CD4+ T cells. Optimized CD4-targeted LNPs transfect up to 48% of non-activated CD4+ T cells within a PBMC co-culture, the highest efficiency reported so far through LNP transfection. Moreover, they successfully deliver CRISPR-Cas9 components to activated CD4+ T cells and achieve up to 32% gene editing. In humanized NSG-SGM3 mice, CD4-targeted LNPs selectively associate with and transfect circulating and bone marrow-resident human CD4+ T cells while showing minimal off-target activity in murine cells. These results establish CD4-nanobody LNPs as a versatile platform for targeted mRNA and gene-editing delivery, with broad potential for cancer immunotherapy, T cell reprogramming, and HIV cure strategies.
Cancer immunotherapy is a transformative technology allowing for the elimination of malignant cells through immune system stimulation; however, the large-scale clinical application of adoptive cellular therapy technologies is limited due to difficulties in ex vivo immune cell engineering, high costs, and complicated ma...
Hari Krishnareddy Rachamala, Sandeep Atla, R. S. Angom· Frontiers in Pharmacology· 0 citations
Non-viral engineering of primary T cells is constrained by low transfection efficiency and significant cargo-induced toxicity. This study evaluates a LGA-PEI (lactic-co-glycolic acid-modified polyethyleneimine) nanoparticle system designed to overcome the recalcitrance of murine T cells, particularly unstimulated, muri...
Priscila Tonon Baschirotto, Christian Marín-Müller, Randall Loaiza-Montoya· International journal of pha...· 0 citations
Engineered extracellular vesicles (EVs) are promising therapeutic carriers for cancer treatment, but preserving intrinsic therapeutic activity while incorporating multiple immunomodulatory functions remains a challenge. Here, we developed a modular engineering strategy that combines the genetic engineering of EV-produc...
Wen-Mo Liu, Ying Yang, Li-Ying Wang et al.· Nano letters (Print)· 0 citations
Background/Objectives: Glioblastoma multiforme (GBM) remains the most aggressive and treatment-refractory primary brain tumor, with current therapeutic modalities providing minimal survival improvement. Chimeric antigen receptor (CAR)-based immunotherapies succeeded in hematologic malignancies but are constrained in so...
What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient. The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.
MIT News · Artificial Intelligence· news.mit.eduNov 12, 2026
MIT scientists developed a training method to generate models that simulate the effects of human activities on climate much more quickly than other approaches.